Navigating the Complexities of Relapsed/Refractory Multiple Myeloma: Novel Treatment Strategies for Improving Outcomes

Released On
December 30, 2020

Expires On
February 27, 2021

Media Type

Completion Time
60 minutes


Multiple Myeloma

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Practicing Clinicians Exchange.

This activity was developed from a series of programs cosupported by educational grants from Astellas; Astellas and Pfizer, Inc; Bristol-Myers Squibb; Celgene Corporation; Eisai Inc; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc, administered by Pharmacyclics, LLC; Taiho Oncology, Inc; and Sanofi Genzyme.

This activity is supported by an educational grant from Sanofi Genzyme, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Pharmacists — maximum of 1.0 contact hours (0.10 CEUs)
  • Nurses — 1.0 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of Oncology NPs, PAs, and nurses.

Program Overview

Relapse in multiple myeloma is inevitable. Thus, the goal of therapy for patients with relapsed/refractory multiple myeloma (RRMM) is to promote deep and durable remissions. In this case-based activity, an expert in multiple myeloma provides a comprehensive review of evidence-based management strategies, including combination therapy, recommended sequencing, and maintenance treatment. In addition, the management of drug-related toxicities and supportive care are reviewed, as they have become even more important with longer survival rates.

Learning Objectives

After completing this activity, participants should be better able to:

  • Screen patients for signs and symptoms of RRMM based on current criteria
  • Formulate treatment approaches for the use of newer agents in patients with RRMM, based on efficacy and safety data, guideline recommendations, and individual patient factors
  • Implement strategies to help mitigate treatment-related adverse effects and promote adherence in patients with MM


Pritesh Patel, MD

Associate Professor of Clinical Medicine
Division of Hematology-Oncology
Associate Director
Blood and Marrow Transplant Program
University of Illinois at Chicago
Chicago, Illinois

Corinne Williams, PA-C

Physician Assistant
Division of Hematology-Oncology
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Immediate Past President
Association of Physician Assistants in Oncology

Joint Accreditation Statement

In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


ANCC Credit Designation
Course director: Lee Schwartzberg, MD, FACP, West Cancer Center, Germantown, Tennessee
CNE course advisor: Stephanie Andrews, MS, ANP-BC, Moffitt Cancer Center, Tampa, Florida
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until February 27, 2021. PAs should only claim credit commensurate with the extent of their participation.


PA course advisor: Emilee Thomas, MMS, MPH, PA-C, Weill Cornell Medicine, New York, New York

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.


Disclosures of Conflicts of Interest

All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are expected to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Pritesh Patel, MD

  • Speakers Bureau: Amgen, Celgene, Janssen

Corinne Williams, PA-C

  • Consultant: AstraZeneca

Lee Schwartzberg, MD, FACP

  • Consultant: Amgen, AstraZeneca, Pfizer

Emilee Thomas, MMS, MPH, PA-C

  • Consultant: Daiichi-Sankyo, OncoSec
  • Speakers Bureau: Genentech

None of the members of the CE Alliance staff have any relevant relationships to disclose.

Instructions for Participation and Credit

Participants wishing to earn CE/CME credit must::

  1. Read the content in its entirety.
  2. Relate the content material to the learning objectives.
  3. Complete the post-test and evaluation form.


Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.

The estimated time to complete this activity is 1.00 hour.


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.

Contact Information

For Practicing Clinicians Exchange general information, contact